Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
  • C07F1/12—Gold compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/28—Compounds containing heavy metals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
  • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
  • C07F1/10—Silver compounds

Definitions

• the present disclosure relates generally to the fields of medicine, pharmaceutical agents, and chemotherapeutics.
• the present disclosure relates to gold carbene naphthoquinone complexes and compositions, which can be used to treat cancer.
• Au(I) bis-N-heterocyclic carbene (NHC) complexes have attracted growing interest due to their interesting catalytic (Hashmi et al., 2000; Nieto-Oberhuber et al., 2004; Mamane et al., 2004; Gorin and Toste, 2007; He et al., 2008; Marion and Nolan, 2008; Haro and Nevado, 2011), luminescent (Lima and Rodr ⁇ guez, 2011; Puddephatt, 2008; Yam and Cheng, 2008; Fernández et al., 2007; Sun et al., 2008; Enomoto et al., 2001) and biological properties (Che and Sun, 2011; Barry and Sadler, 2013; Mora et al., 2019; Berners-Price and Filipovska, 2011; Baker et al., 2006).
• the present disclosure provides compounds that are capable of inducing immunogenic cell death in a cell, such as a cancer cell.
• these compounds comprise a functional group which allows the compound to be to be joined to another compound, such as a cell targeting group or a second anti-cancer therapeutic agent.
• these compounds comprise a metal carbene complex such as Au(I) carbene complex.
• the present disclosure provides compounds of the formula:
• M is an Au or Ag ion
• R 1 and R 2 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CR a R b )C(O)Y 1 ; wherein:
• Y1 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and
• R a and R b are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups; or
• q 1, 2, or 3;
• n 1-10;
• R c is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) , or
• Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof; and R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -X 2 C(O)R 7 ⁇ ; wherein:
• X 2 is a covalent bond, NRg, or O, wherein:
• R g is hydrogen, alkyl (C£6) , or substituted alkyl (C£6) ;
• R 7 ⁇ is hydrazine, alkylhydrazine (C£12) , substituted alkylhydrazine (C£12) , heterocycloalkyl (C£12) , substituted heterocycloalkyl (C£12) , alkoxy (C£8) , substituted alkoxy (C£8) , cycloalkoxy (C£8) , substituted cycloalkoxy (C£8) , aryloxy (C£8) , substituted aryloxy (C£8) , aralkoxy (C£8) , substituted aralkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , substituted dialkylamino (C£8) , cycloalkylamino (C£8) , substituted
• R 3 is hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2 ) r ) y Z 1 , wherein:
• r is 1, 2, or 3;
• y is 0-10
• Z 1 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ;
• R 3 or two or more positions are substituted with R 3 and two of the R 3 groups are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• R 4 and R 5 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CRdRe)C(O)Y 2 ; wherein:
• Y 2 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and
• R d and R e are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups;
• p 1-10;
• R f is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) , or
• Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof; and R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -C(O)R 7 ⁇ ; wherein:
• R 7 ⁇ is alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) ;
• R 6 and R 6 ⁇ are each independently hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2 ) t ) z Z 2 , wherein:
• t is 1, 2, or 3;
• Z 2 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ; or
• R 6 and R 6 ⁇ are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof; m is 1, 2, 3, or 4; and
• X 1 is an anionic species such that the change on X 1 balances the net change on the complex.
• the compounds are further defined as:
• M is an Au or Ag ion
• R 1 and R 2 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CR a R b )C(O)Y 1 ; wherein: Y 1 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and
• Ra and Rb are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups; or a group of the formula: -((CH 2 ) q O) n R c , wherein:
• q 1, 2, or 3;
• n 1-10;
• Rc is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) , or
• Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -C(O)R 7 ⁇ ; wherein:
• R 7 ⁇ is alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) ;
• R 3 is hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2 ) r ) y Z 1 , wherein:
• r is 1, 2, or 3;
• y is 0-10
• Z1 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ;
• R 3 or two or more positions are substituted with R 3 and two of the R 3 groups are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• R 4 and R5 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CRdRe)C(O)Y 2 ; wherein: Y 2 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and R d and R e are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substitute
• s is 1, 2, or 3;
• p 1-10;
• R f is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) , or
• Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -C(O)R 7 ⁇ ; wherein:
• R 7 ⁇ is alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) ;
• R 6 and R 6 ⁇ are each independently hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2 )t)zZ 2 , wherein: t is 1, 2, or 3;
• Z 2 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ; or
• R 6 and R 6 ⁇ are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• n 1, 2, 3, or 4;
• X 1 is an anionic species such that the change on X 1 balances the net change on the complex.
• the compounds are further defined as:
• M is an Au or Ag ion
• R 1 and R 2 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CRaRb)C(O)Y1; wherein: Y 1 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and
• R a and R b are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups; or a group of the formula: -((CH 2 ) q O) n R c , wherein:
• q 1, 2, or 3;
• n 1-10;
• Rc is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) , or
• Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -C(O)R 7 ⁇ ; wherein:
• R 7 ⁇ is alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) ;
• R 4 and R 5 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CR d R e )C(O)Y 2 ; wherein: Y 2 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and
• R d and R e are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups;
• s is 1, 2, or 3;
• p 1-10;
• R f is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) , or
• Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof; and
• R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -X 2 C(O)R 7 ⁇ ; wherein:
• X 2 is a covalent bond, NR g , or O, wherein:
• Rg is hydrogen, alkyl (C£6) , or substituted alkyl (C£6) ;
• R 7 ⁇ is hydrazine, alkylhydrazine (C£12) , substituted alkylhydrazine (C£12) , heterocycloalkyl (C£12) , substituted heterocycloalkyl (C£12) , alkoxy (C£8) , substituted alkoxy (C£8) , cycloalkoxy (C£8) , substituted cycloalkoxy (C£8) , aryloxy (C£8) , substituted aryloxy (C£8) , aralkoxy (C£8) , substituted aralkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , substituted dialkylamino (C£8) , cycloalkylamino (C£8) , substituted
• M is an Au ion such as Au(I). In other embodiments, M is an Ag ion such as Ag(I).
• X 1 is Cl-.
• R 1 is aryl (C£18) or substituted aryl (C£18) .
• R 1 is aryl (C£18) such as phenyl, 2,6-diisopropylphenyl, or 2,4,6-trimethylphenyl. In some embodiments, R 1 is 2,6-diisopropylphenyl.
• R 2 is aryl (C£18) or substituted aryl (C£18) .
• R 2 is aryl (C£18) such as phenyl, 2,6-diisopropylphenyl, or 2,4,6-trimethylphenyl. In some embodiments, R 2 is 2,6-diisopropylphenyl. In some embodiments, R 3 is halo such as fluoro. In some embodiments, R 3 is alkoxy (C£12) or substituted alkoxy (C£12) . In some embodiments, R 3 is alkoxy (C£12) such as methoxy. In some embodiments, R 3 is alkyl (C£12) or substituted alkyl (C£12) . In some embodiments, R 3 is alkyl (C£12) such as methyl.
• R 3 two positions are substituted with R 3 and the R 3 groups are taken together and are alkenediyl (C£12) or substituted alkenediyl (C£12) .
• R 3 are taken together and are alkenediyl (C£12) such as R 3 are taken together and form a phenyl ring.
• m is 2, 3, or 4.
• m is 2 or 4.
• m is 2.
• m is 4.
• at least one of R 4 or R 5 is a group of the formula: -Y 2 -R 7 .
• R 4 is alkyl (C£12) or substituted alkyl (C£12) .
• R 4 is alkyl (C£12) such as methyl, ethyl, or isopropyl.
• R 4 is substituted alkyl (C£12) such as 2-hydroxyethyl.
• R 4 is aryl (C£18) or substituted aryl (C£18) .
• R 4 is aryl (C£18) such as phenyl, 2,6-diisopropylphenyl, or 2,4,6-trimethylphenyl.
• R 4 is 2,4,6-trimethylphenyl.
• R 4 is -(CH 2 CH 2 O)pRf. In some embodiments, p is 2, 3, 4, 5, or 6. In some embodiments, p is 2, 3, or 4. In some embodiments, p is 3. In some embodiments, R f is hydrogen. In other embodiments, Rf is alkyl (C£8) or substituted alkyl (C£8) . In some embodiments, R f is alkyl (C£8) such as methyl. In some embodiments, R 4 is -Y 2 -R 7 . In some embodiments, Y 2 is alkanediyl (C£12) or substituted alkanediyl (C£12) such as -CH 2 CH 2 -. In some embodiments, R 7 is hydroxy.
• R5 is alkyl (C£12) or substituted alkyl (C£12) .
• R 5 is alkyl (C£12) such as methyl, ethyl, or isopropyl.
• R 4 is substituted alkyl (C£12) such as 2-hydroxyethyl.
• R5 is aryl (C£18) or substituted aryl (C£18) .
• R 5 is aryl (C£18) such as phenyl, 2,6-diisopropylphenyl, or 2,4,6-trimethylphenyl.
• R5 is 2,4,6-trimethylphenyl.
• R 5 is -(CH 2 CH 2 O) p R f .
• p is 2, 3, 4, 5, or 6.
• p is 2, 3, or 4.
• p is 3.
• Rf is hydrogen.
• R f is alkyl (C£8) or substituted alkyl (C£8) .
• Rf is alkyl (C£8) such as methyl.
• R5 is -Y 2 -R 7 .
• Y 2 is alkanediyl (C£12) or substituted alkanediyl (C£12) such as -CH 2 CH 2 -.
• R 7 is hydroxy.
• R 6 is hydrogen.
• R 6 ⁇ is hydrogen.
• the compounds are further defined as a cation of the formula:
• the compounds are further defined as a halide salt. In some embodiments, the compounds are further defined as a cation of the formula:
• compositions comprising: (A) a compound described herein; and
• the pharmaceutical compositions are formulated for administration: orally, intraadiposally, intraarterially, intraarticularly, intracranially, intradermally, intralesionally, intramuscularly, intranasally, intraocularly, intrapericardially, intraperitoneally, intrapleurally, intraprostatically, intrarectally, intrathecally, intratracheally, intratumorally, intraumbilically, intravaginally, intravenously, intravesicularly, intravitreally, liposomally, locally, mucosally, parenterally, rectally, subconjunctivally, subcutaneously, sublingually, topically, transbuccally, transdermally, vaginally, in crèmes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, or via localized perfusion.
• the pharmaceutical compositions are formulated as a unit dose.
• the present disclosure provides methods of treating a disease or disorder in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a compound or composition described herein.
• the disease or disorder is cancer.
• cancer is a carcinoma, sarcoma, lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, or seminoma.
• the cancer is of the bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, gall bladder, gastrointestinal tract, genitalia, genitourinary tract, head, kidney, larynx, liver, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate, skin, spleen, small intestine, large intestine, stomach, testicle, or thyroid.
• the cancer is a platinum resistant cancer.
• the platinum resistant cancer is resistant to one platinum chemotherapeutic agent.
• the platinum resistant cancer is resistant to two or more platinum chemotherapeutic agents such as a platinum resistant ovarian cancer, a platinum resistant lung cancer, a platinum resistant mesothelioma, a platinum resistant bladder cancer, a platinum resistant head and neck cancer, a platinum resistant cervical cancer, or a platinum resistant esophageal cancer.
• the compound induces the cells of the cancer to undergo immunogenic cell death.
• the disease is an infection of a parasite.
• the infection is of a parasite associated with a tropical disease.
• the infection is of an intracellular parasite.
• the treatment of the disease or disorder would benefit from the inhibition of thioredoxin reductase.
• the treatment of the disease or disorder would benefit from the increased production of reactive oxygen species.
• the methods comprise administering a second anticancer therapy.
• second anticancer therapy is a chemotherapeutic agent.
• the patient is a mammal such as a human.
• the methods comprise administering the compound once.
• the methods comprise administering the compound two or more times.
• the present disclosure provides methods of inducing immunological cell death in a cell comprising contacting the cell with an effective amount of a compound or composition described herein.
• the present disclosure provides methods of inhibiting thioredoxin reductase comprising administering an effective amount of a compound or composition described herein.
• the present disclosure provides methods of increasing the production of reactive oxygen species in a cell comprising contacting the cell with an effective amount of a compound or composition described herein.
• the method is performed in vitro. In other embodiments, the method is performed in vivo.
• the cell is in a patient.
• the thioredoxin reductase is located in a cell. In some embodiments, the cell is in a patient.
• the present disclosure provides methods of inducing an immune response in a patient comprising administering to the patient a therapeutically effective amount of a compound or composition described herein.
• the immune response is directed towards a specific type of cell.
• the specific type of cell is a cancer cell.
• the immune response leads to cell death in the specific type of cell.
• compositions comprising: (A) a compound described herein; and
• the cancer cell is obtained from a patient. In some embodiments, the cancer cell is obtained from the patient to which the composition is to be administered. In some embodiments, the composition is obtained ex vivo. In some embodiments, the cancer cell or cancer cell extract are combined with the compound ex vivo. In some embodiments, the composition comprises an intact cancer cell. In other embodiments, the composition comprises a cancer cell extract. In some embodiments, the composition is purified to obtain the cancer cell. In still yet another aspect, the present disclosure provides methods of treating cancer in a patient comprising administering a therapeutically effective amount of a composition described above to the patient. In some embodiments, the cancer cell or cancer cell extract is from the patient to which the composition is to be administered. In some embodiments, the cancer cell or cancer cell extract has been purified from the composition. In still another aspect, the present disclosure provides methods of preparing a cancer vaccine comprising: (A) obtaining a cancer cell or cancer cell extract from a patient;
• the method further comprises purifying the cancer vaccine to obtain a purified cancer vaccine comprising the cancer cell or cancer cell extract.
• the purification removes the compound.
• the present disclosure provides conjugates comprising: (A) a compound described herein, wherein at least one of R 1 , R 2 , R 4 , or R 5 is a group of the formula: -Y 2 -R 7 ;
• (C) a cell targeting moiety or a chemotherapeutic agent.
• the linker group is a linker group that is degradable in vivo. In some embodiments, the linker group is a carbamate or carbonate. In some embodiments, the linker group further comprises a self-immolating group. In some embodiments, the linker group is a polypeptide sequence. In some embodiments, the polypeptide sequence is a sequence cleaved by a protease. In some embodiments, the cell targeting moiety is an antibody, an affibody, a peptide or protein, a nucleic acid sequence, or a small molecule. In some embodiments, the chemotherapeutic agent is a small molecule. In yet another aspect, the present disclosure provides compound of the formula:
• M is an Au or Ag ion
• R 1 , R 2 , R 4 , and R 5 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CR d R e )C(O)Y 2 ; wherein:
• Y 2 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and
• R d and R e are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups;
• r is 1, 2, or 3;
• p 1-10;
• Rf is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) , or
• Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -X 2 C(O)R 7 ⁇ ; wherein:
• X 2 is a covalent bond, NRg, or O, wherein:
• R g is hydrogen, alkyl (C£6) , or substituted alkyl (C£6) ;
• R 7 ⁇ is hydrazine, alkylhydrazine (C£12) , substituted alkylhydrazine (C£12) , heterocycloalkyl (C£12) , substituted heterocycloalkyl (C£12) , alkoxy (C£8) , substituted alkoxy (C£8) , cycloalkoxy (C£8) , substituted cycloalkoxy (C£8) , aryloxy (C£8) , substituted aryloxy (C£8) , aralkoxy (C£8) , substituted aralkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , substituted dialkylamino (C£8) , cycloalkylamino (C£8) , substituted cycloalkylamino (C£8) , arylamino (C£8) , substituted ary
• R 6 , R 6 ⁇ , R 6 ", and R 6 " ⁇ each independently hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2 )s)zZ 2 , wherein: s is 1, 2, or 3;
• Z 2 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ; or
• R 6 and R 6 ⁇ or R 6 " and R 6 " ⁇ are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof; or R 6 " and R 6 " ⁇ are taken together and are a group of the formula:
• R 3 is hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2 ) t ) y Z 1 , wherein:
• t is 1, 2, or 3;
• y is 0-10
• Z 1 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ;
• R 3 or two or more positions are substituted with R 3 and two of the R 3 groups are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• n 1, 2, 3, or 4;
• X 1 is an anionic species such that the change on X 1 balances the net change on the complex
• R 1 , R 2 , R 4 , or R 5 is a group of the formula: -Y 2 -R 7 .
• the compounds are further defined as:
• M is an Au or Ag ion
• R 1 and R 2 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CR aRb)C(O)Y1; wherein: Y1 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and
• R a and R b are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups; or a group of the formula: -((CH 2 )qO)nRc, wherein:
• q 1, 2, or 3;
• n 1-10;
• Rc is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) ,
• R 4 and R5 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CRdRe)C(O)Y 2 ; wherein: Y 2 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and
• Rd and Re are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups;
• r is 1, 2, or 3;
• p 1-10;
• Rf is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) , or
• Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -X 2 C(O)R 7 ⁇ ; wherein:
• X 2 is a covalent bond, NRg, or O, wherein:
• R g is hydrogen, alkyl (C£6) , or substituted alkyl (C£6) ;
• R 7 ⁇ is hydrazine, alkylhydrazine (C£12) , substituted alkylhydrazine (C£12) , heterocycloalkyl (C£12) , substituted heterocycloalkyl (C£12) , alkoxy (C£8) , substituted alkoxy (C£8) , cycloalkoxy (C£8) , substituted cycloalkoxy (C£8) , aryloxy (C£8) , substituted aryloxy (C£8) , aralkoxy (C£8) , substituted aralkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , substituted dialkylamino (C£8) , cycloalkylamino (C£8) , substituted cycloalkylamino (C£8) , arylamino (C£8) , substituted ary
• R 6 , R 6 ⁇ , R 6 ", and R 6 " ⁇ each independently hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2 ) s ) z Z 2 , wherein: s is 1, 2, or 3;
• Z 2 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ; or
• R 6 and R 6 ⁇ or R 6 " and R 6 " ⁇ are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof; or R 6 " and R 6 " ⁇ are taken together and are a group of the formula:
• R 3 is hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2 )t)yZ1, wherein:
• t is 1, 2, or 3;
• y is 0-10
• Z 1 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ; or two or more positions are substituted with R 3 and two of the R 3 groups are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• n 1, 2, 3, or 4;
• X 1 is an anionic species such that the change on X 1 balances the net change on the complex
• R 1 , R 2 , R 4 , or R5 is a group of the formula: -Y 2 -R 7 .
• the compounds are further defined as:
• M is an Au or Ag ion
• R 1 and R 2 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CR aRb)C(O)Y1; wherein: Y1 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and
• Ra and Rb are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups; or R 4 and R5 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CR d R e )C(O)Y 2 ; wherein: Y 2 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkyla
• Rd and Re are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups;
• r is 1, 2, or 3;
• p 1-10;
• R f is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) , or
• Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof; and
• R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -X 2 C(O)R 7 ⁇ ; wherein:
• X 2 is a covalent bond, NR g , or O, wherein:
• Rg is hydrogen, alkyl (C£6) , or substituted alkyl (C£6) ;
• R 7 ⁇ is hydrazine, alkylhydrazine (C£12) , substituted alkylhydrazine (C£12) , heterocycloalkyl (C£12) , substituted heterocycloalkyl (C£12) , alkoxy (C£8) , substituted alkoxy (C£8) , cycloalkoxy (C£8) , substituted cycloalkoxy (C£8) , aryloxy (C£8) , substituted aryloxy (C£8) , aralkoxy (C£8) , substituted aralkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , substituted dialkylamino (C£8) , cycloalkylamino (C£8) , substituted cycloalkylamino (C£8) , arylamino (C£8) , substituted ary
• R 6 , R 6 ⁇ , R 6 ", and R 6 " ⁇ each independently hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2 )s)zZ 2 , wherein: s is 1, 2, or 3;
• Z 2 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ; or
• R 6 and R 6 ⁇ or R 6 " and R 6 " ⁇ are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof; or R 6 " and R 6 " ⁇ are taken together and are a group of the formula:
• R 3 is hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2 ) t ) y Z 1 , wherein: t is 1, 2, or 3;
• y is 0-10
• Z 1 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ;
• R 3 or two or more positions are substituted with R 3 and two of the R 3 groups are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• n 1, 2, 3, or 4;
• X 1 is an anionic species such that the change on X 1 balances the net change on the complex
• R 1 , R 2 , R 4 , or R 5 is a group of the formula: -Y 2 -R 7 .
• the compounds are further defined as:
• M is an Au or Ag ion
• R 1 and R 2 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CRaRb)C(O)Y1; wherein: Y1 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and
• Ra and Rb are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups; or R 4 and R5 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CR dRe)C(O)Y 2 ; wherein: Y 2 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (
• Rd and Re are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups;
• r is 1, 2, or 3;
• R f is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) , or
• Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -X 2 C(O)R 7 ⁇ ; wherein:
• X 2 is a covalent bond, NRg, or O, wherein:
• Rg is hydrogen, alkyl (C£6) , or substituted alkyl (C£6) ;
• R 7 ⁇ is hydrazine, alkylhydrazine (C£12) , substituted alkylhydrazine (C£12) , heterocycloalkyl (C£12) , substituted heterocycloalkyl (C£12) , alkoxy (C£8) , substituted alkoxy (C£8) , cycloalkoxy (C£8) , substituted cycloalkoxy (C£8) , aryloxy (C£8) , substituted aryloxy (C£8) , aralkoxy (C£8) , substituted aralkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , substituted dialkylamino (C£8) , cycloalkylamino (C£8) , substituted cycloalkylamino (C£8) , arylamino (C£8) , substituted ary
• R 1 , R 2 , R 4 , or R 5 is a group of the formula: -Y 2 -R 7 .
• R 1 is aryl (C£18) or substituted aryl (C£18) .
• R 1 is aryl (C£18) such as phenyl, 2,6-diisopropylphenyl, or 2,4,6-trimethylphenyl.
• R 1 is 2,6-diisopropylphenyl.
• R 2 is aryl (C£18) or substituted aryl (C£18) .
• R 2 is aryl (C£18) such as phenyl, 2,6-diisopropylphenyl, or 2,4,6-trimethylphenyl.
• R 2 is 2,6-diisopropylphenyl.
• R 4 is aryl (C£18) or substituted aryl (C£18) .
• R 4 is aryl (C£18) such as phenyl, 2,6-diisopropylphenyl, or 2,4,6-trimethylphenyl.
• R 4 is 2,4,6-trimethylphenyl.
• R 6 is hydrogen.
• R 6 ⁇ is hydrogen.
• R 6 2 is hydrogen.
• R 6 " ⁇ is hydrogen.
• R 5 is a group of the formula: -Y 2 -R 7 , wherein: Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof; and
• R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -X 2 C(O)R 7 ⁇ ; wherein:
• X 2 is a covalent bond, NR g , or O, wherein:
• Rg is hydrogen, alkyl (C£6) , or substituted alkyl (C£6) ;
• R 7 ⁇ is hydrazine, alkylhydrazine (C£12) , substituted alkylhydrazine (C£12) , heterocycloalkyl (C£12) , substituted heterocycloalkyl (C£12) , alkoxy (C£8) , substituted alkoxy (C£8) , cycloalkoxy (C£8) , substituted cycloalkoxy (C£8) , aryloxy (C£8) , substituted aryloxy (C£8) , aralkoxy (C£8) , substituted aralkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , substituted dialkylamino (C£8) , cycloalkylamino (C£8) , substituted cycloalkylamino (C£8) , arylamino (C£8) , substituted ary
• Y 2 is alkanediyl (C£12) or substituted alkanediyl (C£12) . In some embodiments, Y 2 is alkanediyl (C£12) such as ethylene.
• R 7 is -X 2 C(O)R 7 ⁇ . In some embodiments, X 2 is O. In some embodiments, R 7 ⁇ is hydrazine. In other embodiments, R 7 ⁇ is aralkamino (C£18) or substituted aralkamino (C£18) . In some embodiments, R 7 ⁇ is aralkamino (C£18) such as 4-t-butyl-phenylmethyl or pyrenylmethyl.
• R 7 ⁇ is arylamino (C£12) or substituted arylamino (C£12) .
• R 7 ⁇ is arylamino (C£12) such as 4-t-butylphenylamino.
• R 7 ⁇ is (alkyl)arylamino (C£12) or substituted (alkyl)arylamino (C£12) .
• R 7 ⁇ is (alkyl)arylamino (C£12) such as (methyl)phenylamino.
• R 7 ⁇ is alkylamino (C£12) or substituted alkylamino (C£12) .
• R 7 ⁇ is substituted alkylamino (C£12) such as 2-N-Boc-aminoethylamino.
• R 7 ⁇ is heterocycloalkyl (C£12) or substituted heterocycloalkyl (C£12) .
• R 7 ⁇ is heterocycloalkyl (C£12) such as morpholinyl.
• R 7 ⁇ is a fluorophore.
• R 7 ⁇ is pyrene.
• R 7 ⁇ is a chemotherapeutic compound.
• R 7 ⁇ is an anticancer antibiotic.
• R 7 ⁇ is an anthracycline such as doxorubicin. In some embodiments, R 7 ⁇ is cycloalkoxy (C£12) or substituted cycloalkoxy (C£12) . In some embodiments, R 7 ⁇ is cycloalkoxy (C£12) such as cyclohexyloxy. In some embodiments, R 7 ⁇ is aralkoxy (C£12) or substituted aralkoxy (C£12) . In some embodiments, R 7 ⁇ is aralkoxy (C£12) such as 4-methylphenylmethyl or napthyloxy. In some embodiments, R 7 ⁇ is a fluorophore.
• R 7 ⁇ is a fluorophore which further comprises a linking group.
• the linking group is an alkanediyl (C£8) such as an ethylene linker.
• the fluorophore is a naphthalimide based fluorophore.
• R 7 ⁇ is an amino acid residue.
• the amino acid residue is connected via the side chain of the amino acid.
• the side chain is a side chain from a canonical amino acid.
• the amino acid is a protected amino acid.
• the amino acid is tyrosine, a serine, or threonine.
• the amino acid is a protected tyrosine, a serine, or threonine.
• X 1 is a monovalent anion such as hexafluorophosphate.
• the compounds are further defined as:
• any method or composition described herein can be implemented with respect to any other method or composition described herein.
• the terms“comprise” (and any form of comprise, such as“comprises” and “comprising”),“have” (and any form of have, such as“has” and“having”),“contain” (and any form of contain, such as“contains” and“containing”), and“include” (and any form of include, such as“includes” and“including”) are open-ended linking verbs.
• a method, composition, kit, or system that“comprises,”“has,”“contains,” or“includes” one or more recited steps or elements possesses those recited steps or elements, but is not limited to possessing only those steps or elements; it may possess (i.e., cover) elements or steps that are not recited.
• an element of a method, composition, kit, or system that“comprises,” “has,”“contains,” or“includes” one or more recited features possesses those features, but is not limited to possessing only those features; it may possess features that are not recited.
• any embodiment of any of the present methods, composition, kit, and systems may consist of or consist essentially of—rather than comprise/include/contain/have—the described steps and/or features.
• the term“consisting of” or“consisting essentially of” may be substituted for any of the open-ended linking verbs recited above, in order to change the scope of a given claim from what it would otherwise be using the open- ended linking verb.
• FIG. 1 shows ORTEP representation of SS-1*PF6, SS-A-1, and SS-A-2e from left to right respectively.
• FIG.2 shows cell proliferation profiles of A549 cell line treated with i) Auranofin, ii) SS-1*PF6, and iii) SS-A-2e (shown from left to right).
• FIGS 3A & 3B show (FIG. 3A) tolerability (mouse body weight) and (FIG. 3B) anticancer efficacy of 3 in nude mice bearing subcutaneous A549 human lung cancer xenografts.3 was administered intravenously on days 1, 3, 5, 7, 10, and 13.
• FIGS. 4A-4E show (FIG.
• FIG. 4A Confocal microscopy analysis of CT26 colon cancer cells illustrating CRT translocation to the cell membrane upon treatment of 3 for 6 hr (red, WGA; blue, DAPI; green, CRT).
• FIG.4B Percent CRT + Panc-02 cells treated with vehicle, oxaliplatin, and variable concentrations of 3, followed by flow cytometric assessment.
• FIG. 4C ATP release from CT26 cells after a 4 hr incubation with varying concentrations of 3.
• FIG. 4D % tumor free mice (i.e., left flank tumor) treated with the respective anticancer vaccine to the right flank and then inoculated (i.e., challenged) with CT26 cells in the left flank.
• FIGS. 5A & 5B show (FIG. 5A) Schematic view of bimodal network targeting. I) Normal (green) signal transduction within a generic biological network. II) In the presence of a small molecule protein inhibitor, the pathway is shut down (black); however, no change in response is observed due to redirection of the signal transduction. III) It is hypothesized that biochemical targeting with the same protein inhibitor in conjunction with a small molecule that induces general pathway stress (e.g., a redox cycler) will shut down the network, resulting in a greater alteration in the phenotypic response. (FIG.
• FIG. 6 shows the ORTEP representation of complex 3 and a functionalized version thereof.
• FIG.7 shows the ORTEP representations of 4 and 6. Hydrogen atoms are omitted for clarity. Thermal ellipsoids are drawn at the 50% probability level. Further details of these structures and that of 5 may be obtained from the Cambridge Crystallographic Centre by making reference to CCDC nos.1999228-1999230.
• FIGS.8A-8D show the (FIG.8A) 5 (100 mM, 2% DMSO in PBS) photographed in the absence (left) and presence (right) of BSA after allowing to mix for 15 min. (FIG.
• FIG.8C shows Confocal microscopic images of A549 lung cancer cells after treatment with (A-C) 1 mM 5, (D-F) 1 mM 5, and BSA (G-I) 5 mM Morpho-Np-OH.
• FIG.9 shows Confocal microscopic images of A549 lung cancer cells after treatment with (A-C) 1 mM 5, (D-F) 1 mM 5, and BSA (G-I) 5 mM Morpho-Np-OH.
• FIG. 10 shows cell proliferation profiles of A549 lung cancer cells treated with complex 1 and complex 5 in the presence and absence of BSA, respectively (72 h drug incubation time).
• Auranofin was used as a reference drug (maximum DMSO: 0.1%).
• FIG.11 shows on the left, the fluorescence spectrum of complex 5 (1 mM) recorded in the absence and presence of 20 mM BSA in PBS. On the right, complex 5 (100 mM) precipitates out as aggregates in the absence of BSA in PBS, whereas in the presence of 600 mM BSA 5 is solubilized.
• FIGS.12A & 12B show HPLC diagram showing:
• FIG.13 shows the ORTEP representation of 1, 4, 10, and 11 rendered using POV-Ray. Thermal ellipsoids are at the 50% probability level.
• FIG.14 shows the cell proliferation profiles of A549 lung cancer cells (ATCC) treated with representative conjugates of the present study as judged by MTT assay after 72 h of incubation. IC50 values derived from these studies are given in Table 9.
• FIG.15 shows the cell proliferation profiles of A549 lung cancer cells treated with 7 and doxorubicin (72 h drug incubation time). Auranofin has been used as a reference drug. (Maximum DMSO: 0.1%.)
• FIG.16 shows the lipoate reduction assay as a method to assess thioredoxin reductase activity. This time dependent live cell imaging assay was conducted with 1.25 mM of respective complex in A549 lung cancer cells.
• FIG.17 shows the excitation and emission spectra of 10 (33 mM in 1% DMSO/water).
• FIG.18 shows the excitation and emission spectra of 10 (5 mM in DMSO).
• FIG.19 shows the fluorescence produced by 10 when excited at 354 nm (33 mM in 1% DMSO/water solution).
• FIG.20 shows the excitation and emission spectra of 7 (10 mM in DMSO).
• FIG.21 shows the excitation and emission spectra of 7 (20 mM in 1% DMSO/H 2 O).
• FIG.22 shows the fluorescence intensity comparison: (light) 1% PBS DMSO mixture emission [slit width 10 mm], excited at 405 nm.
• FIG.23 shows the confocal microscopy images of A549 human lung cancer cells post- treatment with i) vehicle only ii) 5 mM doxorubicin iii) 5 mM Au(I)-NHC-DOX conjugate 7 for 6 h.
• FIGS. 24A-24C show the confocal microscopy images of A549 human lung cancer cell line treated with 10 for 7 h.
• FIG.24A Mitotracker Red channel (excited at 588 nm)
• FIG. 24B 10 (excited at 405 nm)
• FIG.24C Merged image. The overlap indicates that 10 localizes to the mitochondria.
• FIGS.26A & 26B show the confocal microscopy images of A549 human lung cancer cell line treated with only 7 at 5 mM for 6 h.
• FIG.25A Mitotracker Red channel (excited at 588 nm)
• FIG. 25B 8 (excited at 502 nm)
• FIGS.26A & 26B show the confocal microscopy images of A549 human lung cancer cell line treated with only 7 for 6 h imaged at two different concentrations: (FIG.26A) 1 mM (FIG.26B) 500 nM.
• FIG.26A 1 mM
• FIG. 27 shows the confocal microscopy images of A549 human lung cancer cells treated with 5 mM of Au(I)-NHC-Dox conjugate 7, 5 mM doxorubicin and vehicle only for 6 h.
• the nuclear overlay of doxorubicin and the Hoechst dye suggests the nuclear localization of doxorubicin. However, no overlay was observed between 7 and the Hoechst dye leading us to suggest that 7 does not localize to the nucleus.
• 29A & 29B shows the HPLC trace of isolated product monitored at 470 nm (FIG.29A) and at 254 nm (FIG.29B).
• DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS the present disclosure provides gold carbene naphthoquinone compounds which contain two different therapeutically active centers and a functional group which allows the compound to be attached to another group. These compounds may be used in the treatment of cancers including platinum resistant cancers. Furthermore, these compounds may be used to lead to immunogenic cell death and the creation of a cancer vaccine. These compounds and related compositions and methods are described in more detail below.
• the present disclosure relates to compounds of the formula:
• M is an Au or Ag ion
• R 1 , R 2 , R 4 , and R 5 are each independently alkyl (C£12) , cycloalkyl (C£12) , aryl (C£18) , aralkyl (C£18) , or a substituted version of any of these groups; or -(CR d R e )C(O)Y 2 ; wherein:
• Y 2 is amino, hydroxy, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , and
• R d and R e are each independently the side chain of a canonical amino acid or alkyl (C£8) , cycloalkyl (C£8) , aryl (C£12) , aralkyl (C£12) , heteroaryl (C£12) , heteroaralkyl (C£12) , or a substituted version of these six groups;
• r is 1, 2, or 3;
• p 1-10;
• Rf is hydrogen, alkyl (C£8) , or substituted alkyl (C£8) , or
• Y 2 is alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof; and R 7 is amino, carboxy, halo, hydroxy, mercapto, alkoxy (C£8) , substituted alkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , or substituted dialkylamino (C£8) , or -X 2 C(O)R 7 ⁇ ; wherein:
• X 2 is a covalent bond, NRg, or O, wherein:
• R g is hydrogen, alkyl (C£6) , or substituted alkyl (C£6) ;
• R 7 ⁇ is hydrazine, alkylhydrazine (C£12) , substituted alkylhydrazine (C£12) , heterocycloalkyl (C£12) , substituted heterocycloalkyl (C£12) , alkoxy (C£8) , substituted alkoxy (C£8) , cycloalkoxy (C£8) , substituted cycloalkoxy (C£8) , aryloxy (C£8) , substituted aryloxy (C£8) , aralkoxy (C£8) , substituted aralkoxy (C£8) , alkylamino (C£8) , substituted alkylamino (C£8) , dialkylamino (C£8) , substituted dialkylamino (C£8) , cycloalkylamino (C£8) , substituted
• R 6 , R 6 ⁇ , R 6 ", and R 6 " ⁇ each independently hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2)s)zZ 2 , wherein:
• s is 1, 2, or 3;
• Z 2 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ; or
• R 6 and R 6 ⁇ or R 6 " and R 6 " ⁇ are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof; or
• R 6 " and R 6 " ⁇ are taken together and are a group of the formula:
• R 3 is hydrogen, amino, cyano, halo, hydroxy, nitro, thio, or alkyl (C£12) , cycloalkyl (C£12) , aryl (C£12) , heteroaryl (C£12) , aralkyl (C£12) , heteroaralkyl (C£12) , acyl (C£12) , alkoxy (C£12) , alkylamino (C£12) , dialkylamino (C£12) , or a substituted version of any of these ten groups, or -(O(CH 2 ) t ) y Z 1 , wherein:
• t is 1, 2, or 3;
• y is 0-10
• Z1 is hydroxy, alkoxy (C£6) , or substituted alkoxy (C£6) ;
• R 3 or two or more positions are substituted with R 3 and two of the R 3 groups are taken together and are alkanediyl (C£12) , alkenediyl (C£12) , arenediyl (C£18) , heteroarenediyl (C£18) , or a substituted version thereof;
• n 1, 2, 3, or 4;
• X 1 is an anionic species such that the change on X 1 balances the net change on the complex
• R 1 , R 2 , R 4 , or R5 is a group of the formula: -Y 2 -R 7 .
• R 1 , R 2 , R 4 , or R5 is a group of the formula: -Y 2 -R 7 .
• the compounds of the present invention are shown, for example, above, in the summary of the invention section, and in the claims below. They may be made using the synthetic methods outlined in the Examples section. These methods can be further modified and optimized using the principles and techniques of organic chemistry as applied by a person skilled in the art. Such principles and techniques are taught, for example, in Smith, March’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, (2013), which is incorporated by reference herein. In addition, the synthetic methods may be further modified and optimized for preparative, pilot- or large-scale production, either batch or continuous, using the principles and techniques of process chemistry as applied by a person skilled in the art. Such principles and techniques are taught, for example, in Anderson, Practical Process Research & Development– A Guide for Organic Chemists (2012), which is incorporated by reference herein.
• All the compounds of the present invention may in some embodiments be used for the prevention and treatment of one or more diseases or disorders discussed herein or otherwise.
• one or more of the compounds characterized or exemplified herein as an intermediate, a metabolite, and/or prodrug may nevertheless also be useful for the prevention and treatment of one or more diseases or disorders.
• all the compounds of the present invention are deemed“active compounds” and“therapeutic compounds” that are contemplated for use as active pharmaceutical ingredients (APIs).
• APIs active pharmaceutical ingredients
• Actual suitability for human or veterinary use is typically determined using a combination of clinical trial protocols and regulatory procedures, such as those administered by the Food and Drug Administration (FDA).
• FDA Food and Drug Administration
• the FDA is responsible for protecting the public health by assuring the safety, effectiveness, quality, and security of human and veterinary drugs, vaccines and other biological products, and medical devices.
• the compounds of the present invention have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, more metabolically stable than, more lipophilic than, more hydrophilic than, and/or have a better pharmacokinetic profile (e.g., higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological, physical, or chemical properties over, compounds known in the prior art, whether for use in the indications stated herein or otherwise.
• a better pharmacokinetic profile e.g., higher oral bioavailability and/or lower clearance
• Compounds of the present invention may contain one or more asymmetrically- substituted carbon or nitrogen atom and may be isolated in optically active or racemic form. Thus, all chiral, diastereomeric, racemic form, epimeric form, and all geometric isomeric forms of a chemical formula are intended, unless the specific stereochemistry or isomeric form is specifically indicated. Compounds may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. In some embodiments, a single diastereomer is obtained.
• the chiral centers of the compounds of the present invention can have the S or the R configuration. In some embodiments, the present compounds may contain two or more atoms which have a defined stereochemical orientation.
• Chemical formulas used to represent compounds of the present invention will typically only show one of possibly several different tautomers. For example, many types of ketone groups are known to exist in equilibrium with corresponding enol groups. Similarly, many types of imine groups exist in equilibrium with enamine groups. Regardless of which tautomer is depicted for a given compound, and regardless of which one is most prevalent, all tautomers of a given chemical formula are intended.
• atoms making up the compounds of the present invention are intended to include all isotopic forms of such atoms.
• Isotopes include those atoms having the same atomic number but different mass numbers.
• isotopes of hydrogen include tritium and deuterium
• isotopes of carbon include 13 C and 14 C.
• compounds of the present invention function as prodrugs or can be derivatized to function as prodrugs.
• prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.)
• the compounds employed in some methods of the invention may, if desired, be delivered in prodrug form.
• the invention contemplates prodrugs of compounds of the present invention as well as methods of delivering prodrugs.
• Prodrugs of the compounds employed in the invention may be prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
• prodrugs include, for example, compounds described herein in which a hydroxy, amino, or carboxy group is bonded to any group that, when the prodrug is administered to a patient, cleaves to form a hydroxy, amino, or carboxylic acid, respectively.
• compounds of the present invention exist in salt or non-salt form.
• the particular anion or cation forming a part of any salt form of a compound provided herein is not critical, so long as the salt, as a whole, is pharmacologically acceptable. Additional examples of pharmaceutically acceptable salts and their methods of preparation and use are presented in Handbook of Pharmaceutical Salts: Properties, and Use (2002), which is incorporated herein by reference. B. Hyperproliferative Diseases
• hyperproliferative diseases can be associated with any medical disorder that causes a cell to begin to reproduce uncontrollably, the prototypical example is cancer.
• cancer One of the key elements of cancer is that the normal apoptotic cycle of the cell is interrupted and thus agents that lead to apoptosis of the cell are important therapeutic agents for treating these diseases.
• the gold carbene naphthoquinone compounds and compositions described in this disclosure may be effective in treating cancers.
• Cancer cells that may be treated with the compounds according to the embodiments include but are not limited to cells from the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestine, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, pancreas, testis, tongue, cervix, or uterus.
• the cancer may specifically be of the following histological type, though it is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acid
• the tumor may comprise an osteosarcoma, angiosarcoma, rhabdosarcoma, leiomyosarcoma, Ewing sarcoma, glioblastoma, neuroblastoma, or leukemia.
• the cancers treated herein may be associated with one or more specific types of mutations or treated by inducing reactive oxygen species or causing immunogenic cell death including through the use of medicinal metal complexes.
• Medicinal inorganic chemistry is a field of tremendous potential whose promise has yet to be fully realized.
• the only non-radioactive inorganic compounds to have received FDA approval as cancer therapeutics are cisplatin, carboplatin, and oxaliplatin. These compounds are used as front line therapies by oncologists, with roughly half of all cancer patients undergoing chemotherapy receiving one of these three complexes, alone or in combination with other agents (Galanski et al., 2005).
• platins are not devoid of problems, including inter alia dose-limiting toxicities, poor tumor localization, accumulated resistance, and off-target toxicity, it is clear that if other metals could be found that show benefits approaching or surpassing those of platinum, it would have a transformative effect on oncology. This would be particularly true if different modes of action were involved.
• the inventors have created a series of small Au(I)-containing molecules were specifically designed to target a cancer relevant pathway rather than a single protein target (compounds 1 and 2) (Arambula et al., 2016; McCall et al., 2017). However, these systems suffered from poor water solubility and lacked a functional handle that would allow them to be attached to inter alia a targeting agent or derivatized in prodrug form. Therefore, instantly claimed compounds were created including complex 3 that may be formulated for use in vivo and which shows surprising and unexpected high potency.
• cytokines cytokines
• cell-based therapies i.e., cytokines, cell-based therapies, vaccines, immune checkpoint blockade
• major challenges still exist, including low clinical responses (cytokines), high dose-limiting toxicity (cytokines), safety issues (cell based therapies), expense (cell based therapies), a small percentage of patients benefiting (immune checkpoint blockade), and immune related adverse events (immune checkpoint blockade) (Farkona et al., 2016).
• novel approaches to activating an anticancer immunological response are still required.
• Apoptosis via traditional chemotherapy treatment is generally thought to be immune system independent.
• recent data supports the notion that apoptosis follows biochemically distinct subroutines that promote ICD (Savill and Fadok, 2000; Matzinger et al., 2002; Blachère et al., 2005; Casares et al., 2005; Sancho et al., 2008).
• ICD immunodeficiency virus
• TLR-4 patient populations (12-14% mutation rate in humans) in which loss-of-function alleles result in tumor recurrence after treatment with anthracyclines (Ferwerda et al., 2007).
• ICD results in a stepwise process of DC localization to the tumor, phagocytosis of dying/dead tumor cells by DCs, antigen processing by DCs, maturation of DCs, and antigen presentation by DCs to T cells. This cascade culminates in an IFN-g-mediated immune response (Terenzi et al., 2016).
• ROS reactive oxygen species
• Auranofin and other Au(I)-phosphine complexes display moderate antiproliferative activity in several cancer cell lines; however, only limited anti-tumor activity has been observed in vivo (Hill et al., 1989; Mirabelli et al., 1986; Viotte et al., 1996).
• This contrast between in vitro activity and lack of in vivo efficacy is attributed to the lability of the Au(I)-phosphine bond and is compounded by the complexity of the antioxidant pathway.
• the resiliency of the highly-networked antioxidant pathway prevents effective growth inhibition in vivo when only TrxR is targeted (FIG.5A, I ® II).
• pharmaceutical formulations for administration to a patient in need of such treatment, comprise a therapeutically effective amount of a compound disclosed herein formulated with one or more excipients and/or drug carriers appropriate to the indicated route of administration.
• the compounds disclosed herein are formulated in a manner amenable for the treatment of human and/or veterinary patients.
• formulation comprises admixing or combining one or more of the compounds disclosed herein with one or more of the following excipients: lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, as well as cyclodextrins, open chain oligosaccharides, and related carriers.
• the pharmaceutical formulation may be tableted or encapsulated.
• the compounds may be dissolved or slurried in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.
• the pharmaceutical formulations may be subjected to pharmaceutical operations, such as sterilization, and/or may contain drug carriers and/or excipients such as preservatives, stabilizers, wetting agents, emulsifiers, encapsulating agents such as lipids, dendrimers, polymers, proteins such as albumin, nucleic acids, and buffers.
• compositions may be administered by a variety of methods, e.g., orally or by injection (e.g. subcutaneous, intravenous, and intraperitoneal).
• the compounds disclosed herein may be coated in a material to protect the compound from the action of acids and other natural conditions which may inactivate the compound.
• To administer the active compound by other than parenteral administration it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation.
• the active compound may be administered to a patient in an appropriate carrier, for example, liposomes, or a diluent.
• Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Liposomes include water-in- oil-in-water CGF emulsions as well as conventional liposomes. Cyclodextrins and related systems may also be used as excipients.
• Dispersions can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
• compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (such as, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
• the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
• Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
• isotonic agents for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, in the composition.
• Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.
• the compounds disclosed herein can be administered orally, for example, with an inert diluent or an assimilable edible carrier.
• the compounds and other ingredients may also be enclosed in a hard or soft-shell gelatin capsule, compressed into tablets, or incorporated directly into the patient’s diet.
• the compounds disclosed herein may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
• the percentage of the therapeutic compound in the compositions and preparations may, of course, be varied.
• the amount of the therapeutic compound in such pharmaceutical formulations is such that a suitable dosage will be obtained.
• the therapeutic compound may also be administered topically to the skin, eye, ear, or mucosal membranes.
• Administration of the therapeutic compound topically may include formulations of the compounds as a topical solution, lotion, cream, ointment, gel, foam, transdermal patch, or tincture.
• the therapeutic compound may be combined with one or more agents that increase the permeability of the compound through the tissue to which it is administered.
• the topical administration is administered to the eye.
• Such administration may be applied to the surface of the cornea, conjunctiva, or sclera. Without wishing to be bound by any theory, it is believed that administration to the surface of the eye allows the therapeutic compound to reach the posterior portion of the eye.
• Ophthalmic topical administration can be formulated as a solution, suspension, ointment, gel, or emulsion.
• topical administration may also include administration to the mucosa membranes such as the inside of the mouth. Such administration can be directly to a particular location within the mucosal membrane such as a tooth, a sore, or an ulcer.
• the therapeutic compound may be administered by inhalation in a dry-powder or aerosol formulation.
• Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the patients to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
• the specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such a therapeutic compound for the treatment of a selected condition in a patient.
• active compounds are administered at a therapeutically effective dosage sufficient to treat a condition associated with a condition in a patient.
• the efficacy of a compound can be evaluated in an animal model system that may be predictive of efficacy in treating the disease in a human or another animal.
• the effective dose range for the therapeutic compound can be extrapolated from effective doses determined in animal studies for a variety of different animals.
• the human equivalent dose (HED) in mg/kg can be calculated in accordance with the following formula (see, e.g., Reagan-Shaw et al., FASEB J., 22(3):659- 661, 2008, which is incorporated herein by reference):
• HED Animal dose (mg/kg) ⁇ (Animal K m /Human K m )
• BSA body surface area
• K m values for humans and various animals are well known. For example, the Km for an average 60 kg human (with a BSA of 1.6 m 2 ) is 37, whereas a 20 kg child (BSA 0.8 m 2 ) would have a K m of 25.
• mice Km of 3 (given a weight of 0.02 kg and BSA of 0.007); hamster Km of 5 (given a weight of 0.08 kg and BSA of 0.02); rat K m of 6 (given a weight of 0.15 kg and BSA of 0.025) and monkey Km of 12 (given a weight of 3 kg and BSA of 0.24).
• HED dose Precise amounts of the therapeutic composition depend on the judgment of the practitioner and are specific to each individual. Nonetheless, a calculated HED dose provides a general guide. Other factors affecting the dose include the physical and clinical state of the patient, the route of administration, the intended goal of treatment and the potency, stability and toxicity of the particular therapeutic formulation.
• the actual dosage amount of a compound of the present disclosure or composition comprising a compound of the present disclosure administered to a patient may be determined by physical and physiological factors such as type of animal treated, age, sex, body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. These factors may be determined by a skilled artisan.
• the practitioner responsible for administration will typically determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual patient. The dosage may be adjusted by the individual physician in the event of any complication.
• the therapeutically effective amount typically will vary from about 0.001 mg/kg to about 1000 mg/kg, from about 0.01 mg/kg to about 750 mg/kg, from about 100 mg/kg to about 500 mg/kg, from about 1 mg/kg to about 250 mg/kg, from about 10 mg/kg to about 150 mg/kg in one or more dose administrations daily, for one or several days (depending of course of the mode of administration and the factors discussed above).
• Other suitable dose ranges include 1 mg to 10,000 mg per day, 100 mg to 10,000 mg per day, 500 mg to 10,000 mg per day, and 500 mg to 1,000 mg per day.
• the amount is less than 10,000 mg per day with a range of 750 mg to 9,000 mg per day.
• the amount of the active compound in the pharmaceutical formulation is from about 2 to about 75 weight percent. In some of these embodiments, the amount if from about 25 to about 60 weight percent.
• Desired time intervals for delivery of multiple doses can be determined by one of ordinary skill in the art employing no more than routine experimentation.
• patients may be administered two doses daily at approximately 12-hour intervals.
• the agent is administered once a day.
• the agent(s) may be administered on a routine schedule.
• a routine schedule refers to a predetermined designated period of time.
• the routine schedule may encompass periods of time which are identical, or which differ in length, as long as the schedule is predetermined.
• the routine schedule may involve administration twice a day, every day, every two days, every three days, every four days, every five days, every six days, a weekly basis, a monthly basis or any set number of days or weeks there-between.
• the predetermined routine schedule may involve administration on a twice daily basis for the first week, followed by a daily basis for several months, etc.
• the invention provides that the agent(s) may be taken orally and that the timing of which is or is not dependent upon food intake.
• the agent can be taken every morning and/or every evening, regardless of when the patient has eaten or will eat.
• the symbol“ ” means a single bond
• “ ” means a double bond
• “o” means triple bond.
• the symbol represents an optional bond, which if present is either single or double.
• the symbol“ represents a single bond or a double bond.
• the formula covers, for example, and And it is understood that no one such ring atom forms part of more than one double bond.
• the covalent bond symbol“-”, when connecting one or two stereogenic atoms does not indicate any preferred stereochemistry. Instead, it covers all stereoisomers as well as mixtures thereof.
• the symbol“ ”, when drawn perpendicularly across a bond indicates a point of attachment of the group. It is noted
• the symbol“ ” means a single bond where the group attached to the thick end of the wedge is“out of the page.”
• the symbol means a single bond where the group attached to the thick end of the wedge
• the symbol“ ” means a single bond where the geometry around a double bond (e.g., either E or Z) is undefined. Both options, as well as combinations thereof are therefore intended. Any undefined valency on an atom of a structure shown in this application implicitly represents a hydrogen atom bonded to that atom. A bold dot on a carbon atom indicates that the hydrogen attached to that carbon is oriented out of the plane of the paper.
• variable may replace any hydrogen atom attached to any of the ring atoms, including a depicted, implied, or expressly defined hydrogen, so long as a stable structure is formed.
• a variable is depicted as a“floating group” on a fused ring system, as for example the group“R” in the formula:
• variable may replace any hydrogen attached to any of the ring atoms of either of the fused rings unless specified otherwise.
• Replaceable hydrogens include depicted hydrogens (e.g., the hydrogen attached to the nitrogen in the formula above), implied hydrogens (e.g., a hydrogen of the formula above that is not shown but understood to be present), expressly defined hydrogens, and optional hydrogens whose presence depends on the identity of a ring atom (e.g., a hydrogen attached to group X, when X equals -CH-), so long as a stable structure is formed.
• R may reside on either the 5-membered or the 6-membered ring of the fused ring system.
• the subscript letter“y” immediately following the R enclosed in parentheses represents a numeric variable. Unless specified otherwise, this variable can be 0, 1, 2, or any integer greater than 2, only limited by the maximum number of replaceable hydrogen atoms of the ring or ring system.
• the minimum number of carbon atoms in the groups“alkyl (C£8) ”,“cycloalkanediyl (C£8) ”,“heteroaryl (C£8) ”, and“acyl (C£8) ” is one
• the minimum number of carbon atoms in the groups “alkenyl (C£8) ”, “alkynyl (C£8) ”, and “heterocycloalkyl (C £ 8) ” is two
• the minimum number of carbon atoms in the group “cycloalkyl (C£8) ” is three
• the minimum number of carbon atoms in the groups“aryl (C£8) ” and“arenediyl (C£8) ” is six.“Cn-n ⁇ ” defines both the minimum (n) and maximum number (n ⁇ ) of carbon atoms in the group.
• alkyl (C2-10) designates those alkyl groups having from 2 to 10 carbon atoms. These carbon number indicators may precede or follow the chemical groups or class it modifies and it may or may not be enclosed in parenthesis, without signifying any change in meaning.
• the terms“C5 olefin”,“C5-olefin”,“olefin (C5) ”, and“olefin C5 ” are all synonymous. Except as noted below, every carbon atom is counted to determine whether the group or compound falls with the specified number of carbon atoms.
• methoxyhexyl which has a total of seven carbon atoms, is an example of a substituted alkyl (C1-6).
• any chemical group or compound class listed in a claim set without a carbon atom limit has a carbon atom limit of less than or equal to twelve.
• saturated when used to modify a compound or chemical group means the compound or chemical group has no carbon-carbon double and no carbon-carbon triple bonds, except as noted below.
• the term when used to modify an atom, it means that the atom is not part of any double or triple bond.
• substituted versions of saturated groups one or more carbon oxygen double bond or a carbon nitrogen double bond may be present. And when such a bond is present, then carbon-carbon double bonds that may occur as part of keto- enol tautomerism or imine/enamine tautomerism are not precluded.
• saturated when used to modify a solution of a substance, it means that no more of that substance can dissolve in that solution.
• aliphatic signifies that the compound or chemical group so modified is an acyclic or cyclic, but non-aromatic compound or group.
• the carbon atoms can be joined together in straight chains, branched chains, or non-aromatic rings (alicyclic).
• Aliphatic compounds/groups can be saturated, that is joined by single carbon- carbon bonds (alkanes/alkyl), or unsaturated, with one or more carbon-carbon double bonds (alkenes/alkenyl) or with one or more carbon-carbon triple bonds (alkynes/alkynyl).
• aromatic signifies that the compound or chemical group so modified has a planar unsaturated ring of atoms with 4n +2 electrons in a fully conjugated cyclic p system.
• An aromatic compound or chemical group may be depicted as a single resonance structure; however, depiction of one resonance structure is taken to also refer to any other resonance structure. For example: .
• Aromatic compounds may also be depicted using a circle to represent the delocalized nature of the electrons in the fully conjugated cyclic p system, two non-limiting examples of which are shown below:
• alkyl refers to a monovalent saturated aliphatic group with a carbon atom as the point of attachment, a linear or branched acyclic structure, and no atoms other than carbon and hydrogen.
• alkanediyl refers to a divalent saturated aliphatic group, with one or two saturated carbon atom(s) as the point(s) of attachment, a linear or branched acyclic structure, no carbon-carbon double or triple bonds, and no atoms other than carbon and hydrogen.
• the groups -CH 2 - (methylene), -CH 2 CH 2 -, -CH 2 C(CH 3 ) 2 CH 2 -, and -CH 2 CH 2 CH 2 - are non-limiting examples of alkanediyl groups.
• An“alkane” refers to the class of compounds having the formula H-R, wherein R is alkyl as this term is defined above.
• cycloalkyl refers to a monovalent saturated aliphatic group with a carbon atom as the point of attachment, said carbon atom forming part of one or more non-aromatic ring structures, no carbon-carbon double or triple bonds, and no atoms other than carbon and hydrogen.
• Non-limiting examples include: -CH(CH 2 )2 (cyclopropyl), cyclobutyl, cyclopentyl, or cyclohexyl (Cy).
• the term does not preclude the presence of one or more alkyl groups (carbon number limitation permitting) attached to a carbon atom of the non- aromatic ring structure.
• cycloalkanediyl refers to a divalent saturated aliphatic group with two carbon atoms as points of attachment, no carbon-carbon double or triple bonds, and no atoms other than carbon and hydrogen.
• the group is a non-limiting example of cycloalkanediyl group.
• A“cycloalkane” refers to the class of compounds having the formula H-R, wherein R is cycloalkyl as this term is defined above.
• alkenyl refers to a monovalent unsaturated aliphatic group with a carbon atom as the point of attachment, a linear or branched, acyclic structure, at least one nonaromatic carbon-carbon double bond, no carbon-carbon triple bonds, and no atoms other than carbon and hydrogen.
• alkenediyl refers to a divalent unsaturated aliphatic group, with two carbon atoms as points of attachment, a linear or branched acyclic structure, at least one nonaromatic carbon- carbon double bond, no carbon-carbon triple bonds, and no atoms other than carbon and hydrogen.
• alkene and“olefin” are synonymous and refer to the class of compounds having the formula H-R, wherein R is alkenyl as this term is defined above.
• terminal alkene and“a-olefin” are synonymous and refer to an alkene having just one carbon-carbon double bond, wherein that bond is part of a vinyl group at an end of the molecule.
• alkynyl refers to a monovalent unsaturated aliphatic group with a carbon atom as the point of attachment, a linear or branched acyclic structure, at least one carbon- carbon triple bond, and no atoms other than carbon and hydrogen. As used herein, the term alkynyl does not preclude the presence of one or more non-aromatic carbon-carbon double bonds.
• the groups -CoCH, -CoCCH 3 , and -CH 2 CoCCH 3 are non-limiting examples of alkynyl groups.
• An“alkyne” refers to the class of compounds having the formula H-R, wherein R is alkynyl.
• aryl refers to a monovalent unsaturated aromatic group with an aromatic carbon atom as the point of attachment, said carbon atom forming part of a one or more aromatic ring structures, each with six ring atoms that are all carbon, and wherein the group consists of no atoms other than carbon and hydrogen. If more than one ring is present, the rings may be fused or unfused. Unfused rings are connected with a covalent bond. As used herein, the term aryl does not preclude the presence of one or more alkyl groups (carbon number limitation permitting) attached to the first aromatic ring or any additional aromatic ring present.
• Non-limiting examples of aryl groups include phenyl (Ph), methylphenyl, (dimethyl)phenyl, -C 6 H 4 CH 2 CH 3 (ethylphenyl), naphthyl, and a monovalent group derived from biphenyl (e.g., 4-phenylphenyl).
• the term“arenediyl” refers to a divalent aromatic group with two aromatic carbon atoms as points of attachment, said carbon atoms forming part of one or more six- membered aromatic ring structures, each with six ring atoms that are all carbon, and wherein the divalent group consists of no atoms other than carbon and hydrogen.
• arenediyl does not preclude the presence of one or more alkyl groups (carbon number limitation permitting) attached to the first aromatic ring or any additional aromatic ring present. If more than one ring is present, the rings may be fused or unfused. Unfused rings are connected with a covalent bond.
• alkyl groups carbon number limitation permitting
• An“arene” refers to the class of compounds having the formula H-R, wherein R is aryl as that term is defined above. Benzene and toluene are non-limiting examples of arenes.
• aralkyl refers to the monovalent group -alkanediyl-aryl, in which the terms alkanediyl and aryl are each used in a manner consistent with the definitions provided above.
• Non-limiting examples are: phenylmethyl (benzyl, Bn) and 2-phenyl-ethyl.
• heteroaryl refers to a monovalent aromatic group with an aromatic carbon atom or nitrogen atom as the point of attachment, said carbon atom or nitrogen atom forming part of one or more aromatic ring structures, each with three to eight ring atoms, wherein at least one of the ring atoms of the aromatic ring structure(s) is nitrogen, oxygen or sulfur, and wherein the heteroaryl group consists of no atoms other than carbon, hydrogen, aromatic nitrogen, aromatic oxygen and aromatic sulfur. If more than one ring is present, the rings are fused; however, the term heteroaryl does not preclude the presence of one or more alkyl or aryl groups (carbon number limitation permitting) attached to one or more ring atoms.
• heteroaryl groups include benzoxazolyl, benzimidazolyl, furanyl, imidazolyl (Im), indolyl, indazolyl (Im), isoxazolyl, methylpyridinyl, oxazolyl, oxadiazolyl, phenylpyridinyl, pyridinyl (pyridyl), pyrrolyl, pyrimidinyl, pyrazinyl, quinolyl, quinazolyl, quinoxalinyl, triazinyl, tetrazolyl, thiazolyl, thienyl, and triazolyl.
• N-heteroaryl refers to a heteroaryl group with a nitrogen atom as the point of attachment.
• A“heteroarene” refers to the class of compounds having the formula H-R, wherein R is heteroaryl. Pyridine and quinoline are non-limiting examples of heteroarenes.
• heterocycloalkyl refers to a monovalent non-aromatic group with a carbon atom or nitrogen atom as the point of attachment, said carbon atom or nitrogen atom forming part of one or more non-aromatic ring structures, each with three to eight ring atoms, wherein at least one of the ring atoms of the non-aromatic ring structure(s) is nitrogen, oxygen or sulfur, and wherein the heterocycloalkyl group consists of no atoms other than carbon, hydrogen, nitrogen, oxygen and sulfur. If more than one ring is present, the rings are fused. As used herein, the term does not preclude the presence of one or more alkyl groups (carbon number limitation permitting) attached to one or more ring atoms.
• heterocycloalkyl groups include aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydrothiofuranyl, tetrahydropyranyl, pyranyl, oxiranyl, and oxetanyl.
• N-heterocycloalkyl refers to a heterocycloalkyl group with a nitrogen atom as the point of attachment. N-pyrrolidinyl is an example of such a group.
• acyl refers to the group -C(O)R, in which R is a hydrogen, alkyl, cycloalkyl, or aryl as those terms are defined above.
• the groups, -CHO, -C(O)CH3 (acetyl, Ac), -C(O)CH2CH3, -C(O)CH(CH 3)2, -C(O)CH(CH 2)2, -C(O)C 6H5, and -C(O)C 6H4CH3 are non- limiting examples of acyl groups.
• A“thioacyl” is defined in an analogous manner, except that the oxygen atom of the group -C(O)R has been replaced with a sulfur atom, -C(S)R.
• aldehyde corresponds to an alkyl group, as defined above, attached to a -CHO group.
• alkoxy refers to the group -OR, in which R is an alkyl, as that term is defined above.
• Non-limiting examples include: -OCH3 (methoxy), -OCH 2 CH3 (ethoxy), -OCH 2 CH 2 CH 3 , -OCH(CH 3 ) 2 (isopropoxy), or -OC(CH 3 ) 3 (tert-butoxy).
• cycloalkoxy refers to groups, defined as -OR, in which R is cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocycloalkyl, and acyl, respectively.
• R is cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocycloalkyl, and acyl, respectively.
• alkylthio and“acylthio” refers to the group -SR, in which R is an alkyl and acyl, respectively.
• alcohol corresponds to an alkane, as defined above, wherein at least one of the hydrogen atoms has been replaced with a hydroxy group.
• ether corresponds to an alkane, as defined above, wherein at least one of the hydrogen atoms has been replaced with an alkoxy group.
• alkylamino refers to the group -NHR, in which R is an alkyl, as that term is defined above. Non-limiting examples include: -NHCH3 and -NHCH 2 CH3.
• dialkylamino refers to the group -NRR ⁇ , in which R and R ⁇ can be the same or different alkyl groups. Non-limiting examples of dialkylamino groups include: -N(CH3)2 and -N(CH 3 )(CH 2 CH 3 ).
• cycloalkylamino refers to groups, defined as -NHR, in which R is cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocycloalkyl, and alkoxy, respectively.
• R is cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocycloalkyl, and alkoxy, respectively.
• a non-limiting example of an arylamino group is -NHC 6 H 5 .
• dicycloalkylamino dialkenylamino”, “dialkynylamino”, “diarylamino”, “diaralkylamino”,“diheteroarylamino”,“diheterocycloalkylamino”, and“dialkoxyamino”, refers to groups, defined as -NRR ⁇ , in which R and R ⁇ are both cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocycloalkyl, and alkoxy, respectively.
• alkyl(cycloalkyl)amino refers to a group defined as -NRR ⁇ , in which R is alkyl and R ⁇ is cycloalkyl.
• a non-limiting example of an amido group is -NHC(O)CH3.
• one or more hydrogen atom has been replaced, independently at each instance, by -OH, -F, -Cl, -Br, -I, -NH 2 , -NO2, -CO 2H, -CO 2CH3, -CO 2CH2CH3, -CN, -SH, -OCH 3, -OCH 2CH3, -C(O)CH 3, -NHCH3, -NHCH 2 CH3, -N(CH3)2, -C(O)NH 2 , -C(O)NHCH3, -C(O)N(CH3)2, -OC(O)CH3, -NHC(O)CH 3 , -S(O) 2 OH, or -S(O) 2 NH 2 .
• the following groups are non-limiting examples of substituted alkyl groups: -CH 2 OH, -CH 2 Cl, -CF3, -CH 2 CN, -CH 2 C(O)OH, -CH 2 C(O)OCH 3 , -CH 2 C(O)NH 2 , -CH 2 C(O)CH 3 , -CH 2 OCH 3 , -CH 2 OC(O)CH 3 , -CH 2 NH 2 , -CH 2 N(CH3)2, and -CH 2 CH 2 Cl.
• haloalkyl is a subset of substituted alkyl, in which the hydrogen atom replacement is limited to halo (i.e.
• -F, -Cl, -Br, or -I such that no other atoms aside from carbon, hydrogen and halogen are present.
• the group, -CH 2 Cl is a non- limiting example of a haloalkyl.
• fluoroalkyl is a subset of substituted alkyl, in which the hydrogen atom replacement is limited to fluoro such that no other atoms aside from carbon, hydrogen and fluorine are present.
• the groups -CH 2 F, -CF 3 , and -CH 2 CF 3 are non- limiting examples of fluoroalkyl groups.
• Non-limiting examples of substituted aralkyls are: (3-chlorophenyl)-methyl, and 2-chloro-2-phenyl-eth-1-yl.
• the groups, -C(O)CH 2 CF3, -CO2H (carboxyl), -CO 2 CH 3 (methylcarboxyl), -CO 2 CH 2 CH 3 , -C(O)NH 2 (carbamoyl), and -CON(CH3)2, are non-limiting examples of substituted acyl groups.
• the groups -NHC(O)OCH 3 and -NHC(O)NHCH 3 are non-limiting examples of substituted amido groups.
• the compounds may also further comprise a protected amine group such as an amine protected with either a monovalent protecting group or a divalent protected group.
• a protected amine group such as an amine protected with either a monovalent protecting group or a divalent protected group.
• An“active ingredient” (AI) or active pharmaceutical ingredient (API) is the ingredient in a pharmaceutical drug that is biologically active.
• An“amine protecting group” or“amino protecting group” is well understood in the art.
• An amine protecting group is a group which modulates the reactivity of the amine group during a reaction which modifies some other portion of the molecule. Amine protecting groups can be found at least in Greene and Wuts, 1999, which is incorporated herein by reference.
• amino protecting groups include formyl, acetyl, propionyl, pivaloyl, t–butylacetyl, 2–chloroacetyl, 2–bromoacetyl, trifluoroacetyl, trichloroacetyl, o– nitrophenoxyacetyl, a–chlorobutyryl, benzoyl, 4–chlorobenzoyl, 4–bromobenzoyl, 4– nitrobenzoyl, and the like; sulfonyl groups such as benzenesulfonyl, p–toluenesulfonyl and the like; alkoxy- or aryloxycarbonyl groups (which form urethanes with the protected amine) such as benzyloxycarbonyl (Cbz), p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p- nitrobenz
• the“amine protecting group” can be a divalent protecting group such that both hydrogen atoms on a primary amine are replaced with a single protecting group.
• the amine protecting group can be phthalimide (phth) or a substituted derivative thereof wherein the term “substituted” is as defined above.
• the halogenated phthalimide derivative may be tetrachlorophthalimide (TCphth).
• a“protected amino group” is a group of the formula PGMANH- or PGDAN- wherein PGMA is a monovalent amine protecting group, which may also be described as a“monovalently protected amino group” and PGDA is a divalent amine protecting group as described above, which may also be described as a“divalently protected amino group”.
• the terms“comprise,”“have” and“include” are open-ended linking verbs. Any forms or tenses of one or more of these verbs, such as“comprises,”“comprising,”“has,”“having,” “includes” and“including,” are also open-ended.
• any method that“comprises,” “has” or“includes” one or more steps is not limited to possessing only those one or more steps and also covers other unlisted steps.
• the term“effective,” as that term is used in the specification and/or claims, means adequate to accomplish a desired, expected, or intended result.
• Effective amount “Therapeutically effective amount” or“pharmaceutically effective amount” when used in the context of treating a patient or subject with a compound means that amount of the compound which, when administered to the patient or subject, is sufficient to effect such treatment or prevention of the disease as those terms are defined below.
• An“excipient” is a pharmaceutically acceptable substance formulated along with the active ingredient(s) of a medication, pharmaceutical composition, formulation, or drug delivery system. Excipients may be used, for example, to stabilize the composition, to bulk up the composition (thus often referred to as“bulking agents,”“fillers,” or“diluents” when used for this purpose), or to confer a therapeutic enhancement on the active ingredient in the final dosage form, such as facilitating drug absorption, reducing viscosity, or enhancing solubility. Excipients include pharmaceutically acceptable versions of antiadherents, binders, coatings, colors, disintegrants, flavors, glidants, lubricants, preservatives, sorbents, sweeteners, and vehicles.
• the main excipient that serves as a medium for conveying the active ingredient is usually called the vehicle.
• Excipients may also be used in the manufacturing process, for example, to aid in the handling of the active substance, such as by facilitating powder flowability or non-stick properties, in addition to aiding in vitro stability such as prevention of denaturation or aggregation over the expected shelf life.
• the suitability of an excipient will typically vary depending on the route of administration, the dosage form, the active ingredient, as well as other factors.
• IC50 refers to an inhibitory dose which is 50% of the maximum response obtained. This quantitative measure indicates how much of a particular drug or other substance (inhibitor) is needed to inhibit a given biological, biochemical or chemical process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half.
• the term“patient” or“subject” refers to a living mammalian organism, such as a human, monkey, cow, sheep, goat, dog, cat, mouse, rat, guinea pig, or transgenic species thereof.
• the patient or subject is a primate.
• Non-limiting examples of human patients are adults, juveniles, infants and fetuses.
• pharmaceutically acceptable refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues, organs, and/or bodily fluids of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.
• “Pharmaceutically acceptable salts” means salts of compounds disclosed herein which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 2-naphthalenesulfonic acid, 3-phenylpropionic acid, 4,4 ⁇ -methylenebis(3-hydroxy-2-ene- 1-carboxylic acid), 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, acetic acid, aliphatic mono- and dicarboxylic acids, aliphatic sulfuric acids, aromatic sulfuric acids, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, carbonic acid, cinnamic acid, citric acid,
• Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases.
• Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide.
• Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like. It should be recognized that the particular anion or cation forming a part of any salt of this invention is not critical, so long as the salt, as a whole, is pharmacologically acceptable. Additional examples of pharmaceutically acceptable salts and their methods of preparation and use are presented in Handbook of Pharmaceutical Salts: Properties, and Use (P. H. Stahl & C. G. Wermuth eds., Verlag Helvetica Chimica Acta, 2002).
• A“pharmaceutically acceptable carrier,”“drug carrier,” or simply“carrier” is a pharmaceutically acceptable substance formulated along with the active ingredient medication that is involved in carrying, delivering and/or transporting a chemical agent.
• Drug carriers may be used to improve the delivery and the effectiveness of drugs, including for example, controlled-release technology to modulate drug bioavailability, decrease drug metabolism, and/or reduce drug toxicity. Some drug carriers may increase the effectiveness of drug delivery to the specific target sites.
• Examples of carriers include: liposomes, microspheres (e.g., made of poly(lactic-co-glycolic) acid), albumin microspheres, synthetic polymers, nanofibers, protein-DNA complexes, protein conjugates, erythrocytes, virosomes, and dendrimers.
• A“pharmaceutical drug” (also referred to as a pharmaceutical, pharmaceutical preparation, pharmaceutical composition, pharmaceutical formulation, pharmaceutical product, medicinal product, medicine, medication, medicament, or simply a drug, agent, or preparation) is a composition used to diagnose, cure, treat, or prevent disease, which comprises an active pharmaceutical ingredient (API) (defined above) and optionally contains one or more inactive ingredients, which are also referred to as excipients (defined above).
• API active pharmaceutical ingredient
• A“platinum chemotherapeutic agent” is an organic compound which contains platinum as an integral part of the molecule.
• platinum-based chemotherapeutic agents include carboplatin, cisplatin, and oxaliplatin.
• A“platinum resistant” cancer is a cancer in a patient has progressed while receiving platinum chemotherapeutic agent (i.e. the patient is“platinum refractory”), or the patient has progressed within 12 months (for instance, within 6 months) after completing a course of platinum chemotherapeutic agent.
• Prevention includes: (1) inhibiting the onset of a disease in a subject or patient which may be at risk and/or predisposed to the disease but does not yet experience or display any or all of the pathology or symptomatology of the disease, and/or (2) slowing the onset of the pathology or symptomatology of a disease in a subject or patient which may be at risk and/or predisposed to the disease but does not yet experience or display any or all of the pathology or symptomatology of the disease.
• Prodrug means a compound that is convertible in vivo metabolically into an active pharmaceutical ingredient of the present invention.
• the prodrug itself may or may not also have activity with respect in a given indication.
• a compound comprising a hydroxy group may be administered as an ester that is converted by hydrolysis in vivo to the hydroxy compound.
• Non-limiting examples of suitable esters that may be converted in vivo into hydroxy compounds include acetates, citrates, lactates, phosphates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene- bis-b-hydroxynaphthoate, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates, quinates, and esters of amino acids.
• a compound comprising an amine group may be administered as an amide that is converted by hydrolysis in vivo to the amine compound.
• “selectively” means that greater than 50% of the activity of the compound is exhibited in the noted location.
• “preferentially” means that greater than 75% of the activity of the compound is exhibited in the noted location.
• A“stereoisomer” or“optical isomer” is an isomer of a given compound in which the same atoms are bonded to the same other atoms, but where the configuration of those atoms in three dimensions differs.
• “Enantiomers” are stereoisomers of a given compound that are mirror images of each other, like left and right hands.
• “Diastereomers” are stereoisomers of a given compound that are not enantiomers.
• Chiral molecules contain a chiral center, also referred to as a stereocenter or stereogenic center, which is any point, though not necessarily an atom, in a molecule bearing groups such that an interchanging of any two groups leads to a stereoisomer.
• the chiral center is typically a carbon, phosphorus or sulfur atom, though it is also possible for other atoms to be stereocenters in organic and inorganic compounds.
• a molecule can have multiple stereocenters, giving it many stereoisomers.
• the total number of hypothetically possible stereoisomers will not exceed 2 n , where n is the number of tetrahedral stereocenters.
• Molecules with symmetry frequently have fewer than the maximum possible number of stereoisomers.
• a 50:50 mixture of enantiomers is referred to as a racemic mixture.
• a mixture of enantiomers can be enantiomerically enriched so that one enantiomer is present in an amount greater than 50%.
• enantiomers and/or diastereomers can be resolved or separated using techniques known in the art. It is contemplated that that for any stereocenter or axis of chirality for which stereochemistry has not been defined, that stereocenter or axis of chirality can be present in its R form, S form, or as a mixture of the R and S forms, including racemic and non-racemic mixtures.
• the phrase“substantially free from other stereoisomers” means that the composition contains £ 15%, more preferably £ 10%, even more preferably £ 5%, or most preferably £ 1% of another stereoisomer(s).
• Treatment includes (1) inhibiting a disease in a subject or patient experiencing or displaying the pathology or symptomatology of the disease (e.g., arresting further development of the pathology and/or symptomatology), (2) ameliorating a disease in a subject or patient that is experiencing or displaying the pathology or symptomatology of the disease (e.g., reversing the pathology and/or symptomatology), and/or (3) effecting any measurable decrease in a disease or symptom thereof in a subject or patient that is experiencing or displaying the pathology or symptomatology of the disease.
• unit dose refers to a formulation of the compound or composition such that the formulation is prepared in a manner sufficient to provide a single therapeutically effective dose of the active ingredient to a patient in a single administration.
• unit dose formulations include but are not limited to a single tablet, capsule, or other oral formulations, or a single vial with a syringeable liquid or other injectable formulations.
• the hydroxyl-functionalized imidazolium proligand were first synthesized by reacting mesitylimidazole with little excess of bromoethanol (Scheme 1) in THF which resulted in 90% yield of the imidazolium bromide 1*Br.
• the other synthon [Au(IPr)OH] was prepared as described by Nolan et. al., by reacting [Au(IPr)Cl] with excess NaOH in presence of t AmOH as a catalyst.
• [Au(IPr)OH] and 1*Br were mixed in dry toluene and heat up at 90 °C to obtain a white precipitate as the crude product.
• the target pyrene-conjugated product SS-2e can be isolated with moderate yield (50%) and it has been fully characterized using 1 H, 13 C, and HRMS. Suitable crystals of SS-2e were also grown using slow diffusion of DEE in DCM solution (ORTEP representation shown in FIG.1).
• Fluorescence microscopy studies reveal that the lmax for excitation is 342 nm whereas l max of emission lies at 395 nm with an excimer emission at 470 nm.
• the fluorescence spectrum can be tuned by wisely choosing the fluorescent probe. For example, changing the pyrene moiety to naphthalimide shifts the l max for excitation to 414 nm.
• an FDA approved anti-cancer drug Doxorubicin was chosen.
• Doxorubicin an anthracyclin type drug that slows or stops the growth of cancer cells by blocking the enzyme topoisomerase 2 has also a primary amine.
• Aromatic amines present in various pharmaceuticals such as the anti-leprosy drug dapson and some antimalarials (e.g. primaquin), are known to be very weak nucleophiles and often need activating agent for coupling reactions.
• a scheme which utilized hydroxybenzotriazole (HOBt) as the activating agent and used DMF as a solvent (Scheme 2) was developed.
• HOBt hydroxybenzotriazole
• Table 1 Types of different amines attached via newly developed methodologies.
• Solvents were either dried with a solvent purification system (DCM, acetonitrile, methanol) or dried over molecular sieves (toluene) (3 ⁇ ) and degassed prior to use.
• DCM solvent purification system
• acetonitrile methanol
• molecular sieves toluene (3 ⁇ )
• the 1 H NMR and 13 C NMR spectra were measured on Varian Inova spectrometers at the University of Texas at Austin using CD 2 Cl 2 and DMSO-d 6 as deuterated solvents. The chemical shifts were reported relative to the residual solvent protons.
• spin multiplicities the following abbreviations were used: s (singlet), d (doublet), t (triplet) and m (multiplet), as well as appropriate combinations of these.
• conjugate drugs are exhibiting great promise because of their dual targeting or multi-targeting mechanism of action.
• the compounds were tested against a A549 lung cancer cell line. As the triplicated 3 day MTT study suggests, these conjugates are highly cytotoxic against that cell line.
• FIG. 2 demonstrates the comparative cell proliferative profile of these carbamate conjugates. This high cytotoxicity could, in part, emerge from the high lipophilic nature of these complexes which help them permeate through the cell membrane easily and target the mitochondria.
• Au(I)-NHC conjugates were used as in vitro cellular imaging agent.
• Au(I)NHC-DOX conjugate turned out to be the best amongst them when A549 human lung cancer cell lines were used for confocal microscopy. After using MItotracker Red to stain mitochondria, overlap of bright red spots from Mitotracker Red and green spots from Au(I)-DOX conjugate were seen. Therefore, the merged image on the right in Fig. 5 clearly indicates the mitochondria as the primary target, which is in accordance with the literature.
• the primary target for Doxorubicin.HCl is mainly the nucleus, as evident from the microscopy images and in accordance with the literature. This evidence is consistent with the positively charged Au(I)-NHC, functionalized with doxorubicin, playing the pivotal role in mitochondrial localization.
• the initial rationale for preparing complexes 1-3 involved a systems approach to circumventing the antioxidant network that helps give solid tumors their resiliency. These compounds were believed to be able to 1) inhibit the production of reducing metabolites (e.g., TrxR/Trx), thereby reducing the ability of the cancer cell to maintain ROS homeostasis and 2) accentuate exogenous ROS production via the use of a redox cycling agent (e.g., ferrocene, naphthoquinone) (Arambula et al., 2016; McCall et al., 2017).
• a redox cycling agent e.g., ferrocene, naphthoquinone
• Compound 3 were developed with a view to improving potency and obtaining a system with features that might make them suitable for development as a potential drug leads.
• complexes 1–3 were designed to 1) inhibit TrxR (leading to a reduction in biological antioxidants) and 2) accentuate exogenous ROS (via redox cycling).
• ICD is mediated by oxidative stress response mechanisms localized to the mitochondria and ER.
• Calreticulin (CRT) translocation from the ER to the cell membrane is a critical mechanistic step in ICD induction.
• murine cancer cell lines Panc-02 pancreas and CT26 colon
• mice were subcutaneously immunized on the right flank with CT26 mouse colorectal cancer cells (3 ⁇ 10 6 ) that were pretreated with varying concentrations (5, 10, or 100 ⁇ M) of 3 for 4 hours (so as to induce the desired ICD biomarkers and creating a potential anticancer vaccine). Seven days later, the mice were challenged subcutaneously in the opposite flank (i.e. left flank) with na ⁇ ve CT26 cells (5 ⁇ 10 5 ) and the challenge tumor growth was monitored over time (FIG.4D).
• Protocol 1 Aromatic alcohol, dry dichloromethane (DCM), triethylamine (TEA), 24 h.
• Protocol 2 Aliphatic or benzylic alcohol, dimethylaminopyridine (DMAP), dry DCM, 24 h. Note– yields (shown in brackets) were calculated based on isolated product.
• Scheme 4 summarizes the reaction chemistry used to produce carbonate functionalized Au(I) bis-NHCs of generalized structure 3 from the starting hydroxyethyl Au(I) bis-NHC 1.
• Protocols 1 and 2 proved successful for the conjugation of alcohols containing amino acids yielding modified tyrosine, serine, and threonine linked Au(I)-bis NHCs 8-10.
• Peptides and amino acid analogues have been widely used in anticancer therapy, (Le Joncour and Laakkonen, 2018; Marques et al., 2017) with amino-acids linked Pt(II) complexes displaying promise as anticancer agents (Rijal et al., 2014; Kimutai et al., 2019).
• the conjugation of tertiary alcohols with 2 proved unsuccessful.
• naphthalimide-based conjugate 5 was of particular interest owing to the fact that it contains a fluorescent moiety tethered to the putative Au(I)-bis NHC therapeutic core.
• naphthalimide derivatives are recognised for their ability to stabilize serum albumin-drug interactions (Fan et al., 2019; Sun et al., 2011). This was viewed as attractive in the context of developing Au(I) complexes as potential drug leads.
• the highly lipophilic nature of most Au(I) bis-NHCs have limited their full biological evaluation (Porchia et al., 2018; Zou et al., 2015).
• naphthalimide-based Au(I) bis-NHC 5 might bind to serum albumins, thus boosting its effective solubility.
• FIG.8A in their native form both 1 and 5 precipitate from aqueous solution after a 15-minute incubation period at a concentration relevant for in vivo studies (100 mM, 2% DMSO in phosphate buffered solution).
• concentration relevant for in vivo studies 100 mM, 2% DMSO in phosphate buffered solution.
• solutions of 5 remained transparent even after incubation for 6 days at 37 °C (FIG.8A).
• K q The bimolecular quenching constants, K q , calculated from the associated Stern-Volmer plots were found to be (3.8 ⁇ 0.3) x 10 12 and (1.4 ⁇ 0.2) x 10 13 M -1 s -1 for complexes 1 and 5, respectively. These values are consistent with binding and thus static quenching between the BSA and the Au(I) complexes in question (Liu et al., 2018). See Table 4.
• complex 5 contains a naphthalimide subunit, which was expected to allow its cellular uptake to be followed via confocal microscopy. Moreover, the large stokes shift ( ⁇ 140 nm) seen for 5 could make it attractive for fluorescence imaging (Sedgwick et al., 2018). Most Au(I) bis-NHCs are cationic and, as a result, typically localize in the mitochondria (Hickey et al., 2008; Sen et al., 2019).
• the analytical column was a Syncronis C18 column, 5 ⁇ m, 4.6 ⁇ 250 mm (Thermo Scientific); the mobile phase containing 0.1% acetic acid consisted of an increasing gradient from 10% acetonitrile/water to 99% acetonitrile/water over 30 min at a flow rate of 1.2 ml/min.
• BSA was purchased from Sigma-Aldrich and used without further purification. All fluorescence measurements for the titrations against BSA were recorded from 300 to 400 nm with an excitation wavelength of 290 nm. The emission and excitation slit widths were fixed at 5 mm. In these measurements, 20 mM BSA stock solutions were prepared in PBS buffer and diluted down to 5 mM.
• [1][PF6] (300 mg, 0.312 mmol, 1 equiv.) and 4-nitrophenyl chloroformate (377.3 mg, 1.872 mmol, 6 equiv.) were combined in an oven-dried two-neck round bottom and kept under vacuum for 15 min. Dry DCM (7 mL) and dry DIPEA (75 mL, 0.468 mmol, 1.5 equiv.) were added to the mixture. Dry pyridine (30 mL) was then added to the mixture. The resulting solution was stirred for 48 h to achieve the full conversion as indicated by LCMS. The volatiles were evaporated off and diethyl ether was added. A white solid precipitated out after stirring for 15 mins and subjecting to trituration.
• Precursor 2 (1 equiv.) was kept under vacuum for 15 mins in an oven-dried two-neck round bottomed flask. Dry DCM (4 ml) and the aromatic alcohol of interest (3 equiv.) were then added. After stirring the mixture for 10 min, dry TEA (2 equiv.) was added and whole mixture was stirred under an N 2 atmosphere for 24 h. After confirming the completion of the reaction by LCMS, the volatiles were evaporated off and diethyl ether was added. The solid precipitate that resulted was collected by filtration. The solid was repeatedly washed with diethyl ether and dried under air.
• Precursor 2 (40 mg, 0.035 mmol) was used along with b-naphthol (15 mg, 0.105 mmol, 3 equiv.) and dry TEA (10 mL, 0.070 mmol, 2 equiv.) with the reaction run in 5 mL dry DCM. A white microcrystalline powder was obtained as the product. Crystals were grown via slow diffusion using DCM/diethyl ether. Yield: 29 mg (74%).
• ESI-HRMS acetonitrile
• Precursor 2 (40 mg, 0.035 mmol) was used along with methyl (tert-butoxycarbonyl)-L- tyrosinate (31 mg, 0.105 mmol, 3 equiv.) and dry TEA (10 mL, 0.070 mmol, 2 equiv.) with the reaction run in 5 mL dry DCM. The product was obtained as a white microcrystalline powder. Yield: 27 mg (60%).
• ESI-HRMS acetonitrile
• Precursor 2 (1 equiv.) and dry DMAP (3 equiv.) were kept under vacuum for 5 mins in an oven-dried two-neck round bottomed flask. Dry DCM (4 mL) and the alcohol of interest (3 equiv.) were then added. The whole mixture was stirred under N 2 atmosphere for 24 h. After confirming the completion of the reaction by LCMS, the volatiles were evaporated off. Diethyl ether was then added to the residue. The solid precipitate that resulted was collected by filtration, washed with diethyl ether, and dried under air. Finally, it was purified by means of a small silica gel chromatography column using 5% MeOH/95% DCM collecting the fraction at R f ⁇ 0.4.
• Precursor 2 (40 mg, 0.035mmol) was used along with Morpho-Np-OH (20 mg, 0.056 mmol, 1.6 equiv.) and dry DMAP (13 mg, 0.105 mmol, 3 equiv.) with the reaction run in 5 mL dry DCM.
• the product was obtained as a yellow microcrystalline powder. Crystals could be grown from DCM/diethyl ether via slow diffusion. Yield: 19 mg (40%).
• ESI-HRMS acetonitrile
• Precursor 2 (40 mg, 0.035 mmol) was used along with p-tolylmethanol (13 mg, 0.105 mmol, 3 equiv.) and dry DMAP (13 mg, 0.105 mmol, 3 equiv.) with the reaction run in 5 mL dry DCM.
• the product was obtained as a white microcrystalline powder. Crystals could be grown via slow diffusion using DCM/diethyl ether. Yield: 21 mg (54%).
• ESI-HRMS acetonitrile
• Precursor 2 (40 mg, 0.035mmol) was used along with cyclohexanol (11 mL, 0.105 mmol, 3 equiv.) and dry DMAP (13 mg, 0.105 mmol, 3 equiv.) in 5 mL dry DCM.
• the product was obtained as a white microcrystalline powder. Crystals could be grown via slow diffusion using DCM/diethyl ether. However, the resulting crystals proved hard to mount and did not diffract well. Yield: 15 mg (43%).
• ESI-HRMS acetonitrile
• Precursor 2 (40 mg, 0.035 mmol) was used along with methyl (tert-butoxycarbonyl)- L-serinate (commercially available as 95% pure) (22 mL, 0.105 mmol, 3 equiv.) and dry DMAP (13 mg, 0.105 mmol, 3 equiv.) in 5 mL dry DCM. White microcrystalline powder was obtained as product. Yield: 18 mg (43%).
• ESI-HRMS acetonitrile
• Precursor 4 (40 mg, 0.035 mmol) was used along with methyl (tert-butoxycarbonyl)- L-threoninate (commercially available in 95% purity) (22 mL, 0.105 mmol, 3 equiv.) and dry DMAP (13 mg, 0.105 mmol, 3 equiv.) with the reaction run in 5 mL dry DCM. The product was obtained as a white microcrystalline powder. Yield: 14 mg (33%).
• ESI-HRMS acetonitrile
• A549 cells were harvested and seeded into 96-well culture plates (Costar 07-200-90) in 100 ⁇ L of culture medium. The cells were allowed to incubate overnight at 37 °C in the presence of 5% CO2. A549 cells were seeded at a density of 1500 cells/well. The next day, appropriate serial dilutions of drug stocks in culture media were made. To each well of a 96 well plate was added 100 ⁇ L of the appropriate solution.
• Tumor cells were harvested and seeded at a density of 2 ⁇ 10 5 cells/dish in 35 mm dishes containing a poly-D lysine coated 10 mm glass diameter (Mat Tek P35GC-1.5-10-C) overnight. Cells were then incubated with respective doses of different complexes at 37 oC for 4 h. Post incubation, the media was removed and cells were washed (2 ⁇ ) with PBS. To the cells was added a PBS solution containing 50 nM Mitotracker ® Red FM (Lifetech M22425) for 30 min at 37 °C. After incubation, the dye PBS solution was removed and the cells were washed with PBS (2 ⁇ ).
• the cells were then imaged fluorescently on a Zeiss LSM 710 laser scanning confocal microscope using a Plan-Apo 63x/1.4 oil objective.
• the green channel was excited with a 405 nm laser, and the emission was detected spectrally from 482 - 555 nm.
• the red channel was excited with a 561 nm laser, and the emission was detected spectrally from 573 - 639 nm.
• a 100 mM solution of complex 5 was incubated with 40 mg/ml (600 mM) BSA at 37 °C for 1 h (final DMSO conc.2%). The stock solution was further diluted 100-fold in RPMI media giving 5 at a final concentration of 1 mM.
• Protocol 1 In the presence of 2-3 equivalents of amine, dichloromethane and triethylamine (i.e., Protocol 1), complete conversion to the corresponding conjugate was observed by HPLC and LCMS when the amine was i) activated (5), ii) primary in its basic form (6), iii) primary in the form of the corresponding hydrochloride salt (7), iv) secondary (8), and v) benzylic (9, 10). Purification of conjugates 7 was affected by HPLC chromatography, whereas purification of 10 was performed using column chromatography over silica gel using 20:1 CH 2 Cl2/methanol (v/v) as the eluent.
• Protocol 1 proved ineffective for preparing carbamate conjugates of aromatic amines.
• Aromatic amines are present in many pharmaceuticals, such as the anti-leprosy drug dapsone and some antimalarials (e.g. primaquine). However, they are relatively weak nucleophiles and often require activation for coupling reactions. Hence, the coupling conditions was modified to include hydroxybenzotriazole (HOBt) as the activating agent and DMF as a solvent (Protocol 2).
• HOBt hydroxybenzotriazole
• DMF solvent
• complexes that might allow SAR insights to be obtained, various amine classes were used to prepare derivatives of 4. Specific amine motifs were chosen due to their prevalence in therapeutics or because they are recognised as having biological utility. For example, the morpholine motif present in complex 8 was chosen because it is a known pharmacophore that appears in a number of cancer therapeutics (Arshad et al., 2019). Likewise, complex 7 contains doxorubicin, an approved anticancer agent (Tacar et al., 2013).
• Au(I) complexes including various Au(I) NHC complexes, inhibit thioredoxin reductase (TrxR), an enzyme that is overexpressed in multiple cancers and thought to be a potential biological target for cancer treatment (McCall et al., 2017; Arambula et al., 2016; Porchia et al., 2018; Mora et al., 2019, Hickey et al., 2008; Zhang et al., 2017; Lu et al., 2007).
• RhxR thioredoxin reductase
• the A549 human lung cancer cell line known to overexpress TrxR, was chosen for study (Cell et al., 2001).
• Auranofin was used as a validated positive control in these tests of anticancer activity due to its recognized ability to inhibit TrxR (Zhang et al., 2019; Marzano et al., 2007).
• the aforementioned complexes were screened for their ability to inhibit cancer cell growth using an MTT assay. It was found that all of conjugates produced in the context of the present study displayed high anticancer potency in the A549 cell line, providing inhibition constants (IC50) varying from 0.11 mM (conjugate 8) to 0.56 mM (conjugate 7) (see Table 8). See FIG.14.
• Table 8 Combined listing of IC50 values of different conjugates a
• A549 lung cancer cells were treated with each complex and subsequently subjected to fluorescent microscopic imaging (cf. FIGS.23-27).
• Mitochondrial localization of Au-bis-NHCs is well validated (Hickey et al., 2008, Berners-Price and Filipovska, 2011), and this proved true for both complexes 7 and 10 as inferred from the fluorescent overlap of the emission signal from each complex and the mitochondrial probe Mitotracker Red (FIGS.23 & 24).
• fluorescent imaging of the mitochondria could be achieved at probe concentrations as low as 500 nM (see FIG.26).
• such low concentrations could not be used effectively in the case of complex 10 since it is not effectively excited at a wavelength (e.g., 405 nm) compatible with the fluorescent microscopic imaging set up (see FIG.22).
• Precursor 4 (1 equiv.) was kept under vacuum for 15 mins in an oven-dried two-neck round bottomed flask. Dry DCM (4 mL) and the amine of interest (2-3 equiv.) were then added. After stirring the mixture for 10 min, dry TEA (2 equiv.) was added and whole mixture was stirred under N 2 atmosphere for 12-36 h. After confirming the completion of the reaction by LCMS, the DCM was evaporated and to that diethyl ether was added. The solid precipitate was subsequently filtered. Finally, the solid was collected and 4 mL of nanopore water was added to it and stirred for another 15 min. The remaining solid was filtered and washed with 5 mL water and hexanes respectively.
• A549 Cells were harvested and seeded into 96-well culture plates (Costar 07-200-90) in 100 ⁇ L of culture media. They were allowed to incubate overnight at 37 °C in the presence of 5% CO 2 . A549 cells were seeded at a density of 1500 cells/well. The next day, appropriate serial dilutions of drug stocks in culture media were made. To each well of a 96 well plate was added 100 ⁇ L of the appropriate solution.
• Live Cell Imaging Assay A549 cells were harvested and seeded at a density of 10,000 cells/well in 96-well culture plates. Following an overnight incubation at 37 °C and 5% CO2, appropriate serial dilutions of drug stocks in culture media were performed, and 100 ⁇ L of the appropriate solution were added to each well. Cells were further incubated for 6 h. Thereafter, the media solution was removed from each well and washed with 200 mL of HBSS solution. Finally, 100 ⁇ L of 5 mM Lipoate (Tokyo Chemical Industry Co., Ltd. L0207) and 1 mM of DTNB (Acros Organics 117540050) solution were added to each well. The absorbance of each well at 405 nm was recorded immediately and once every 20 min for three hours on a microplate reader. Plates were covered with aluminum foil between readings.
• Tumor cells were harvested and seeded at a density of 2 ⁇ 10 5 cells/dish in 35 mm dishes containing a poly-D lysine coated 10 mm glass diameter (Mat Tek P35GC-1.5-10-C) overnight. Cells were then incubated with respective doses of different complexes at 37 °C 4-7 h. Post incubation, the media was removed and cells were washed (2 ⁇ ) with PBS. To the cells was added a PBS solution containing 1 mg/mL Hoechst 33342 (Lifetech H1399) and 50 nM Mitotracker Red FM (Lifetech M22425) for 30 min at 37 °C. After incubation, the dye PBS solution was removed and cells were washed with PBS (2 ⁇ ).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Tropical Medicine & Parasitology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=73459479

Family Applications (1)

Country Status (11)

Citations (2)

Family Cites Families (3)

• 2020
  • 2020-05-22 KR KR1020217041752A patent/KR20220024123A/ko not_active Ceased
  • 2020-05-22 EP EP20809519.0A patent/EP3972981A4/en not_active Withdrawn
  • 2020-05-22 MX MX2021014195A patent/MX2021014195A/es unknown
  • 2020-05-22 SG SG11202112856QA patent/SG11202112856QA/en unknown
  • 2020-05-22 CA CA3140716A patent/CA3140716A1/en active Pending
  • 2020-05-22 US US17/595,670 patent/US12577262B2/en active Active
  • 2020-05-22 JP JP2021569297A patent/JP2022532801A/ja active Pending
  • 2020-05-22 CN CN202080050300.4A patent/CN114174305A/zh active Pending
  • 2020-05-22 WO PCT/US2020/034415 patent/WO2020237225A1/en not_active Ceased
  • 2020-05-22 AU AU2020279478A patent/AU2020279478A1/en not_active Abandoned
• 2021
  • 2021-11-16 IL IL288176A patent/IL288176A/en unknown

Patent Citations (2)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events